Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$67.85M

FY 2025 · Annual

Investing Cash Flow

$113.02M

FY 2025 · Annual

Financing Cash Flow

-$48.50M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Depreciation & Amortization292K427K554K534K621K
Deferred Income Tax49K0000
Stock-Based Compensation10.58M11.52M14.34M13.5M12.52M
Change in Working Capital(10.23M)402K2.66M14.24M(26.89M)
Accounts Receivables381K(14K)(982K)(2.46M)1.09M
Inventory00(381K)150K(50K)
Accounts Payables(14.16M)76K6.45M14.8M(30.22M)
Other Working Capital3.55M340K(2.43M)1.75M2.29M
Other Non-Cash Items54K744K(2.33M)(6.65M)(3.75M)
Operating Cash Flow(87.02M)(88.85M)(161.9M)(178.78M)(67.85M)
Capital Expenditures(1.22M)(1.33M)(470K)(1.03M)0
Acquisitions (Net)(3.33M)69.75M000
Purchases of Investments(34.26M)(133.95M)(223.34M)(338.05M)(143.55M)
Sales of Investments37.59M64.2M173.87M314.4M252.86M
Other Investing Activities3.33M(69.75M)09.31M3.71M
Investing Cash Flow2.11M(71.08M)(49.94M)(15.38M)113.02M
Debt Repayment(11.7M)48.87M49.96M0(48M)
Common Stock Issued37.08M94.21M138.82M64K73K
Common Stock Repurchased(2.68M)(864K)(824K)(1.73M)0
Dividends Paid00000
Other Financing Activities094.21M0(1.24M)(572K)
Financing Cash Flow22.71M142.21M187.96M238.35M(48.5M)
Effect of Forex Changes00000
Net Change in Cash(62.2M)(17.72M)(23.88M)44.19M(3.33M)
Free Cash Flow(88.24M)(90.18M)(162.37M)(179.81M)(67.85M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$50.3M
+ D&A$621.0K
+ Stock-Based Comp$12.5M
+ Deferred Tax$0
- Working Capital-$26.9M
- Other Non-Cash-$3.8M
= Operating Cash Flow-$67.9M
- Capex$0
= Free Cash Flow-$67.9M

Analysis

FY2025 free cash flow is -$67.9M. FCF conversion is 134.8% of net income. Operating cash flow was -$67.9M, with capex of $0. The largest bridge item is Working Capital at -$26.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 9, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
EFFECTEFFECT filingAug 14, 2026

Does LXRX generate free cash flow?

Lexicon Pharmaceuticals, Inc. (LXRX) generated -$67.85M of free cash flow in fiscal 2025.

How much operating cash flow does LXRX produce?

Operating cash flow was -$67.85M, before capital expenditures of $0.00.